



MEDIGARD LIMITED
Suite 14, 30 Tedder Avenue, Main Beach QLD 4217 Australia
Telephone +61 7 5578 7822; Fax +61 7 5528 4459
E-mail: office@medigard.com.au www.medigard.com.au
ABN 49 090 003 044

ASX ANNOUNCEMENT

Chairman's Address

Annual General Meeting 30 November 2017

Welcome everybody,

It is good to see some familiar faces (and some that I do not recognise). Thank you for coming.

As I mentioned in the 2017 annual report, it has been another challenging year for Medigard with limited income and modest progress. I am pleased, however, to be able to talk about several exciting things that have happened since I wrote that report.

Firstly, I would like to welcome our new executive director, Dr Ian Dixon. Ian brings significant market knowledge, intellectual property and relationships to Medigard. He has a track record of building value in advanced medical-related products and technologies, including two clinical stage public companies with market caps of around \$60 million. As part of his appointment, Ian will receive 40 million options at 10 cents and 40 million at 20 cents, subject to shareholders' approval, indicating Ian's serious commitment to growing Medigard. Ian will give a brief presentation after this AGM.

You will have also seen our announcements that \$300,000 has been committed over the last few months in a placement by three of the directors, the company secretary and some sophisticated investors, although the shares associated with the commitments by the directors will only be issued following approval of shareholders. These funds will provide the working capital needed by Medigard to meet its more immediate objectives. The total number of shares on issue is now almost 94 million which at the current share price as of yesterday of 2.4 cents means that Medigard has a current market cap of approximately \$2.3 million.

It is also pleasing that in the last couple of weeks Sol Millennium Medical Products has agreed to extend the maturity date of convertible notes held by them to January 2019. This is a clear indication that Medigard continues to have the confidence and support of Sol Millennium. Sol

Millennium still believes that our blood collection device is a superior product offering the highest level of safety and we look forward to expanding our syringe technology with their help.

As mentioned in the Annual Report, over the past 12 months Medigard has been investigating ways that it can continue its commercialisation activities in the life-sciences and advanced syringe technology. The directors have identified some significant opportunities in higher-value products, including prefilled syringes and we are close to entering into a Master Services Agreement that will provide us access to some exciting innovative technologies developed by a variety of Australian researchers. The directors look forward to being able to announce some of these exciting opportunities to you in the near future, opportunities that will continue Medigard's focus on developing advanced technology that improves people's health and well-being and delivers good commercial outcomes to you, our patient shareholders.

Thank you.

Chris Bishop
Chairman